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Human immunodeficiency virus type 1 (HIV-1) disease is as-
sociated with aberrant immune activation, and coinfection
with hepatitis C virus (HCV) exacerbates hepatic inflamma-
tion and fibrosis. However, the role of HIV-1 infection or
host immune modulation in liver pathogenesis is not clearly
defined. Here, we report that regulatory T (Treg) cells
prevent liver immunopathogenesis during HIV-1 infection
in a humanized mouse model. In the absence of Treg cells,
HIV-1 infection induced liver fibrosis associated with
hepatic stellate cell activation, hepatitis, and liver injury. Our
findings provide new insight linking Treg cells and liver im-
munopathogenesis during HIV-1 infection.
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Immune hyperactivation and progressive loss of CD4+ T cells,
including regulatory T (Treg) cells, are associated with human
immunodeficiency virus type 1 (HIV-1) disease progression
[1]. CD4+CD25+ Treg cells play a critical role in modulating the
immunopathogenesis of a number of diseases, including auto-
immune and infectious diseases [2]. In HIV-infected patients
or simian immunodeficiency virus–infected rhesus macaques,
Treg cells are accumulated and infected in acutely infected
hosts, but numbers are gradually reduced during chronic path-
ogenic infection [3]. However, the role of Treg cells in HIV-1
infection and pathogenesis is not clearly defined, because of a
lack of a robust model. We have recently reported that func-
tional Treg cells are developed in all lymphoid organs in hu-
manized mice. In addition, Treg cells are preferentially
infected, and depletion of Treg cells before HIV-1 infection in
humanized mice leads to an elevated immune response and
reduced HIV-1 replication [4].
Liver disease has become a leading cause of non-AIDS–
related mortality because HIV-infected patients continue to
live longer because of successful antiretroviral therapy. HIV-1–
infected patients are often infected with hepatitis C virus
(HCV) because the pathogens share transmission routes [5].
HIV/HCV coinfection leads to accelerated hepatic fibrosis and
to higher rates of liver failure and death, compared with HCV
monoinfection [5]. Furthermore, HIV-1–infected patients have
a significant risk of liver fibrosis, even without hepatitis virus
coinfection [6]. Both virologic and immunologic mechanisms
have been postulated [5]. However, the role of Treg cells in
hepatic immunopathology during HIV-1 infection with or
without HCV coinfection is unclear. We hypothesized that
Treg cells played a role in modulating liver diseases during
HIV-1 infection. We determined the role of Treg cells in liver
fibrosis during HIV-1 infection in vivo, using a humanized
mouse model.
METHODS
Construction of Humanized Mice
Approval for animal work was obtained from the University of
North Carolina Institutional Animal and Use Committee.
Rag2−/− IL-2Rγ−/− or NOD-scid IL-2Rγ−/− mice were used to
create humanized mice. We constructed humanized mice as
previously reported [4]. In brief, human CD34+ hematopoietic
stem cells were isolated from liver tissue of human fetuses with
a gestational age of 16–18 weeks. Tissue was first perfused with
liver perfusion medium then with liver-digest medium (Invi-
trogen, Frederick, MD). The cell suspension was filtered
through a 70-µm cell strainer (BD Falcon, Lincoln Park, NJ)
and centrifuged at 150 g for 5 minutes to collect mononuclear
cells. Cell viability, measured using Guava Easy Cyte (Millipore,
Billerica, MA), generally exceeded 90%. After selection with the
CD34 magnetic-activated cell sorting kit (Miltenyi Biotech,
Gladbach, Germany), the purity of CD34+ cells was >95%.
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Between 0.5× 106 and 1 × 106 CD34+ cells were injected into
the liver of each 1–5-day-old mouse, which had been previously
irradiated at 400 or 250 rad. Leukocyte populations in >95% of
the mice were stably reconstituted with human leukocytes in
the blood (percentage of leukocyte population composed of
human leukocytes, >10% at 12–14 weeks of age). Humanized
mice in each cohort (ie, mice in which leukocyte populations
were reconstituted from the same human donor fetal liver
tissue) had a similar level of engraftment. All mice were housed
at the University of North Carolina–Chapel Hill.
Treg Cell Depletion by Denileukin Diftitox and HIV-1 Infection
in Humanized Mice
Denileukin diftitox (Ontak; 150 µg/mL in citrate buffer) was
provided by Ligand Pharmaceuticals (San Diego, CA). For in
vivo treatment, humanized mice with leukocyte populations
stably reconstituted with human leukocytes 12–16 weeks after
CD34+ cell transfer (percentage of leukocyte population com-
posed of human CD45+ leukocytes, >10%) were injected retro-
orbitally (2 days before HIV-1 infection) or intraperitoneally
(15 days after infection) with denileukin diftitox at 31 µg/kg of
mouse weight diluted in Hank’s balanced salt solution (HBSS).
HBSS-injected humanized mice were used as controls. Either
denileukin diftitox–injected or HBSS-injected humanized mice
were retro-orbitally infected with HIV-R3A stocks which is a
CCR5/CXCR4 dual tropic and highly pathogenic virus (1 ng
p24/mouse in 50µL). Humanized mice infected with mock
stocks were included as control groups. At the time of euthani-
zation (20 days after infection), blood, spleen, and liver were
harvested, and cell numbers were counted by Guava Easy Cyte.
Flow Cytometry Analysis
At the time of euthanization, lymphocytes were isolated from
the liver tissue by the ACK lysis method. Lymphocytes were
stained with anti-human CD45, CD25, CD4, CD8, and CD3
(Biolegend, San Diego, CA); mouse CD45 (Invitrogen); and the
Live/Dead Fixable dead cell stain kit (Invitrogen). The Cytofix/
Cytoperm kit (BD Bioscience, San Jose, CA) and anti-HIV-1
p24 antibody (Beckman Coulter, Fullerton, CA) were used for
intracellular p24 staining. Stained cells were fixed and analyzed
by CyAn ADP (Dako, Glostrup, Denmark).
Immunohistochemistry Staining and Area Quantification
Paraffin-embedded sections of livers from humanized mice
were stained with hematoxylin and eosin, Sirius red/fast green,
or primary antibodies. After the incubation of sections with
primary antibodies, primary antibodies were detected with Rat
and Mouse Double Stain kit (Biocare Medical, Concord, CA).
The slides were developed with the Betazoid DAB chromogen
kit or the Vulcan Red chromogen kit 2 (Biocare medical).
Slides were observed using an Eclipse E600 microscopy system
(Nikon, Garden City, NY) with a 10× or 20× nonoil objective
and a 10× ocular lens. Images were captured using OmniVid
microscope camera (LW Scientific, Lawrenceville, GA). For
area quantification, pictures were taken with a 4× nonoil objec-
tive and a 10× ocular lens. Pictures were analyzed by ImageJ
(available at: http://rsbweb.nih.gov/ij; developed by Wayne
Rasband, National Institutes of Health, Bethesda, MD) to
quantify positive signals. At least 5 pictures from each liver
were used to quantify positive areas.
Alanine Transaminase (ALT) and Hyaluronic Acid Levels in
Plasma
Blood specimens from humanized mice were obtained at indi-
cated time points, using ethylenediaminetetraacetic acid as an
anticoagulant. Plasma was then prepared by centrifugation.
Plasma ALT and hyaluronic acid levels were measured by the
ALT Color Endpoint Assay kit (Bioo Scientific, Austin, TX)
and the hyaluronic acid ELISA kit (Echelon, Salt Lake City, UT),
respectively.
Gene Expression Analysis
Liver tissue was harvested from each humanized mouse and
stored using RNAlater (Qiagen, Germantown, MD). Total
RNA was extracted from liver tissue, using the RNeasy Plus
Mini Kit (Qiagen). Complementary DNA was reverse tran-
scribed using Super Script III reverse transcriptase (Invitrogen).
Human- and mouse-specific tissue inhibitor of metalloprotei-
nase 1 (TIMP-1) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) real-time quantitative polymerase chain
reaction (qPCR) primers were designed and described previ-
ously [7]. The real-time qPCR primers for human interleukin 6
(IL-6), tumor necrosis factor α (TNF-α), monocyte chemotac-
tic protein 1 (MCP-1), macrophage inflammatory protein 1α
(MIP-1α), and α-smooth muscle actin (SMA) were previously
reported [8, 9]. Gene expression was examined using Thermo
Scientific SYBR green real-time PCR reagents (Thermo Scien-
tific, Waltham, MA). GAPDH was used to normalize messen-
ger RNA (mRNA) expression. mRNA expression was shown by
either fold induction or arbitrary relative expression.
Statistical Analysis
Unpaired 2-tailed Student t tests and 1-way analysis of variance
with the Bonferroni multiple comparison test were performed
using GraphPad Prism (GraphPad Software, San Diego, CA). A
P value of < .05 was considered statistically significant. All data
were reported as mean ± SD.
RESULTS
We used the interleukin 2–toxin fusion protein denileukin dif-
titox to deplete CD4+CD25hi Treg cells from humanized mice.
A single denileukin diftitox injection significantly decreased
CD4+CD25hi Treg cells in blood and lymphoid organs from
humanized mice with no significant effect on other human leu-
kocytes, including CD4+CD25− or CD8+ T cells (Supplementary
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Figure 1 and the article by Jiang et al [4]). To define the role of
Treg cells in hepatitis during HIV-1 infection, we quantified
liver proinflammatory cytokine and chemokine expression. We
found that expression of the human proinflammatory cytokines
IL-6 and TNF-α was increased in the denileukin diftitox group.
Their expression was further increased in the HIV-1 plus deni-
leukin diftitox group (Figure 1A and 1B). Interestingly, expres-
sion of the human inflammatory chemokines MCP-1 and
MIP-1α was highly upregulated by denileukin diftitox alone in
the liver (Figure 1C and 1D), and HIV-1 infection showed no
significant further induction.
To detect leukocyte infiltration in the liver, we stained liver
sections with hematoxylin and eosin and human leukocyte
markers. We detected significant leukocyte infiltration only in
the liver of the HIV-1 plus denileukin diftitox group (Figure 1E
and 1H). The infiltrated leukocytes included human CD45+
cells, CD3+ T cells, and CD68+ macrophages (CD45, CD3, and
CD68; Figure 1E ). They also included Ki-67+ proliferating cells
(Ki-67; Figure 1E ) and p24+ HIV-infected cells (Supplementary
Figure 2A). Consistently, infiltrated human leukocyte numbers
were significantly increased only in the HIV-1 plus denileukin
diftitox group (Figure 1F and Supplementary Figure 3A and
2B). These data suggested that Treg cell depletion and HIV-1
infection cooperatively induced inflammatory cytokines/che-
mokines and hepatitis in the liver.
To detect liver injury associated with hepatitis, we measured
ALT levels in the plasma. ALT levels were significantly elevated
only in mice from HIV-1 plus denileukin diftitox group 20
days after infection (Figure 2A). These data suggest that Treg
cells prevent HIV-1–induced liver damage in humanized mice.
We further measured the plasma hyaluronic acid level, which is
a marker of hepatic injury and fibrosis. Similar to ALT levels,
no significant increase of plasma hyaluronic acid levels was
found in recipients of mock stock, mock stock plus denileukin
diftitox, and HIV-1. However, we detected significantly elevat-
ed hyaluronic acid levels only in the HIV-1 plus denileukin dif-
titox group 20 days after infection (Figure 2B). Consistent with
the elevated liver inflammation and injury, we observed that
livers from mice in the HIV-1 plus denileukin diftitox group
showed significant pathology (Figure 2C).
To further investigate the liver immunopathogenesis, we
stained liver sections with Sirius red/fast green. We observed
significant collagen deposition in the parenchymal area only in
the livers from mice in the HIV-1 plus denileukin diftitox
group (Figure 2D and 2E ). Activation of hepatic stellate cell
and their transition to myofibroblast is a key step for liver fibro-
sis development, and activated hepatic stellate cells (or myofi-
broblasts) express glial fibrillary acidic protein (GFAP) [10] and
α-SMA. To determine hepatic stellate cell activation in the
liver, we stained liver sections with antibodies specific to
human GFAP and α-SMA. We found that GFAP and α-SMA
expression was clearly associated with collagen deposition
(Figure 2D and 2E and data not shown). We further quantified
liver fibrosis by measuring expression of TIMP-1 in the liver.
Expression of human (but not mouse) TIMP-1 mRNA in the
liver of HIV-1 plus denileukin diftitox group was significantly
induced (Figure 2F). Therefore, depletion of Treg cells and
HIV-1 infection cooperatively lead to liver inflammation and
fibrosis.
DISCUSSION
Our findings indicate that Treg cells prevent HIV-1–induced
liver fibrosis associated with hepatic stellate cell activation, hep-
atitis, and liver injury. Consistent with recent reports [11],
MCP-1 is likely to play an important role in the fibrogenic
process initiated by inflammation in HIV-1–induced liver fi-
brosis. MCP-1 may serve as both fibrogenic mediator and che-
moattractant for leukocytes to the liver. Moreover, a low Treg
frequency was observed in HCV-infected patients, compared
with healthy controls [12]. Treg cell depletion is likely to induce
inflammation and fibrosis in virus-induced liver fibrosis (Sup-
plementary Figure 3C and 3D). However, Treg cells were re-
ported to be infiltrated in HCV-infected liver [12]. It would be
interesting to determine the role of intrahepatic Treg cells in
liver fibrosis. Interestingly, although HIV-1 p24+ cell counts
were reduced in spleens (Supplementary Figure 2B and the
article by Jiang et al [4]), HIV-1 p24+ cells significantly infiltrat-
ed fibrotic livers (Supplementary Figure 2A). Both HIV-1 and
human leukocytes can promote human hepatic stellate cell acti-
vation [5, 13, 14]. HIV-1 infection and liver inflammation by
Treg cell depletion cooperatively induces liver fibrosis. It will be
of great interest to elucidate the molecular mechanism of Treg
cells in protecting liver fibrosis during HIV-1 infection in
future experiments.
The origin of the human hepatic stellate cells or myofibro-
blasts [13] in the humanized mouse is currently not clear. Bone
marrow–derived cells can contribute significantly to myofibro-
blast populations during induction of liver fibrosis and cirrho-
sis [15]. Transdifferentiation of myofibroblasts from bone
marrow–derived cells may be induced by HIV-1 infection and
Treg cell depletion. Alternatively, these cells may be derived
from human liver stem or progenitor cells in the CD34-
enriched progenitor populations isolated from fetal livers [13].
Humanized mouse models still have some limitations in the
study of liver disease in human hepatic virus infection, includ-
ing low human cell engraftment and reduced immune activity.
In addition, R3A is a highly pathogenic HIV-1 strain. Thus, it
is important to confirm the findings with less pathogenic HIV-1
isolates in the future. We have recently developed a novel hu-
manized mouse model that has a human immune system and
human hepatic cells [7]. Our findings provide new insight
linking Treg cells and liver immunopathogenesis during HIV-1
infection. With this model, we will be able to test the role of
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Figure 1. Regulatory T (Treg) cell depletion and human immunodeficiency virus type 1 (HIV-1) infection lead to hepatitis. Humanized mice received
mock stock or HIV-1 2 days after treatment with denileukin diftitox (Ontak; 150 µg/mL in citrate buffer; Ligand Pharmaceuticals [San Diego, CA]). Different
groups of mice were euthanized 20 days after infection. A–D, Human interleukin 6 (hIL-6; A), tumor necrosis factor α (hTNF-α; B), monocyte chemotactic
protein 1 (hMCP-1; C), and macrophage inflammatory protein 1α (hMIP-1α; D) messenger RNA expression in the liver was analyzed by real-time quantita-
tive polymerase chain reaction. Fold induction relative to values for recipients of mock stock are shown. Seven mice per group were analyzed. **P < .05, by
1-way analysis of variance with the Bonferroni test. Data are mean ± SD. E, Liver sections obtained 20 days after infection were stained with hematoxylin
and eosin (HE) or with anti-human CD45, CD3, CD68 (Dako), and anti-Ki-67 (Abcam) antibodies. Pictures were taken at 100× magnification. F, Intrahepatic
human leukocyte (CD45) and T-cell (CD3) numbers in different groups of mice are shown. Seven mice per group were analyzed. **P < .05, compared with
mock stock, mock stock plus denileukin diftitox, and HIV-1 recipients, as above. Data are mean ± SD.
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Figure 2. Depletion of regulatory T (Treg) cells during human immunodeficiency virus type 1 (HIV-1) infection induces liver fibrosis. A and B, Blood was
collected 20 days after infection. Plasma alanine aminotransferase (ALT; A) and hyaluronic acid (HA; B) levels were measured. Seven mice per group were
analyzed. C, Representative liver morphology from each group of mice at the time of euthanization is shown. D, Liver sections were stained with Sirius
red/fast green for collagen detection or with anti-human glial fibrillary acidic protein (GFAP) antibodies (Abcam). Pictures were taken at 100× magnification
for all groups and at 200× for the HIV-1 plus denileukin diftitox (Ontak; 150 µg/mL in citrate buffer; Ligand Pharmaceuticals [San Diego, CA]) group. E,
Sirius red–positive (left) or GFAP-positive (right) areas in the liver were quantified by ImageJ. At least 5 images from each liver were used to quantify the
areas. F, Human and mouse tissue inhibitor of metalloproteinase 1 (TIMP-1) messenger RNA expression in the liver was analyzed by real-time quantitative
polymerase chain reaction. Seven mice per group were analyzed. **P < .05 for all analyses, compared with mock stock, mock stock plus denileukin diftitox,
and HIV-1 recipients, by 1-way analysis of variance with the Bonferroni test. Data are mean ± SD.
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Treg cells in liver diseases induced by HIV/HCV coinfection.
Modulating Treg cells may provide a new approach to pre-
venting liver fibrosis in patients coinfected with HIV-1 and
HCV.
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